Q4 2025 SeaStar Medical Holding Corp Earnings Call Transcript
Key Points
- SeaStar Medical Holding Corp (ICU) expanded the use of QUELIMMUNE therapy for ultra-rare pediatric AKI, adding 13 new customers from top-rated children's hospitals.
- The company reported net revenue of over $1 million from QUELIMMUNE sales in 2025, with gross profit margins above 90%.
- SeaStar Medical advanced the development of SCD therapy for adult AKI, achieving over 50% enrollment in the pivotal trial.
- The company improved its balance sheet by adding approximately $24 million in capital and reducing operating liabilities by over $3 million.
- SeaStar Medical received breakthrough device designation from the FDA for SCD therapy, potentially expediting the PMA approval process.
- The pediatric AKI market is small, with a total market opportunity of about $100 million, limiting immediate revenue potential.
- Enrollment in the neutralized AKI pivotal trial is ongoing, with completion targeted around the end of 2026, delaying potential revenue from adult AKI treatment.
- The company faces challenges in expanding QUELIMMUNE adoption, requiring significant effort to add new pediatric hospital sites.
- SeaStar Medical's net loss for 2025 was $12.2 million, indicating ongoing financial challenges despite revenue growth.
- The company must navigate regulatory hurdles, including FDA approvals and site-level IRB approvals, which could delay commercialization.
Good day and thank you for standing by. Welcome to the SeaStar Medical's Q4 2025 financial results conference call. (Operator Instructions)
I would not like to hand the conference over to your speaker today, Jackie Cossmon.
Thank you, Josh. Good afternoon and thank you for joining the SeaStar Medical fourth-quarter and year-end 2025 financial results conference call. I'm Jackie Cossmon with Wheelhouse Life Science Advisors. Joining me from SeaStar Medical today are Eric Shlorff, Chief Executive Officer; Dr. Kevin Chung, Chief Medical Officer; Tim Veracek, Senior Vice President of Commercial and Business Operations; and Mike Messinger, Chief Financial Officer.
I would like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
